RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rigel Pharmaceuticals Inc (RIGL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the financial performance in Q4 2025 was impressive, the technical indicators suggest a bearish trend with the stock being oversold. Additionally, the company's projected revenue decline for 2026 raises concerns about future growth. Given the lack of strong trading signals and mixed sentiment, it's better to hold off on investing right now.
The stock is currently in a bearish trend. The MACD histogram is negative and expanding, indicating downward momentum. The RSI is at 13.879, which shows the stock is oversold. Moving averages are converging, and the price is below the pivot point of 32.542, with key support levels at 29.234 and 27.19.
The company reported strong Q4 2025 financials, with revenue up 21.19% YoY, net income up 1769.22% YoY, and EPS up 1557.50% YoY. Gross margin also improved to 91.47%, reflecting operational efficiency.
The company projects a revenue decline for 2026, estimating total revenue between $275 million and $290 million, alongside a significant drop in contract revenue. This raises concerns about future growth and profitability.
In Q4 2025, Rigel Pharmaceuticals demonstrated strong financial performance with revenue of $69.8 million, net income of $268.1 million, and EPS of $13.26. These figures reflect significant YoY growth, driven by strong market demand and profitability improvements.
No recent analyst rating or price target changes were provided. However, Wall Street sentiment appears mixed given the strong Q4 performance but concerns about future revenue declines.
